SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
出版年份 2019 全文链接
标题
SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
作者
关键词
-
出版物
NEPHROLOGY DIALYSIS TRANSPLANTATION
Volume 34, Issue 2, Pages 208-230
出版商
Oxford University Press (OUP)
发表日期
2019-01-26
DOI
10.1093/ndt/gfy407
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial
- (2018) Stephen D. Wiviott et al. AMERICAN HEART JOURNAL
- Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
- (2018) Eduardo Flores et al. CARDIOVASCULAR DRUGS AND THERAPY
- Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data from the CANVAS Program
- (2018) Brendon L. Neuen et al. CIRCULATION
- Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
- (2018) Karin Rådholm et al. CIRCULATION
- Cardiovascular Effects of New Oral Glucose-Lowering Agents
- (2018) André J. Scheen CIRCULATION RESEARCH
- Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
- (2018) M. ANGELYN BETHEL et al. DIABETES
- GLP-1 receptor agonists and cardiovascular protection: A class effect or not?
- (2018) André J. Scheen DIABETES & METABOLISM
- Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study
- (2018) John B. Buse et al. DIABETES CARE
- Effects of Pentoxifylline on Soluble Klotho Concentrations and Renal Tubular Cell Expression in Diabetic Kidney Disease
- (2018) Juan F. Navarro-González et al. DIABETES CARE
- Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists
- (2018) André J. Scheen DIABETES RESEARCH AND CLINICAL PRACTICE
- Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®
- (2018) Bernard Zinman et al. DIABETOLOGIA
- Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
- (2018) Beatrice C. Lupsa et al. DIABETOLOGIA
- Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
- (2018) Subodh Verma et al. DIABETOLOGIA
- Effects of incretin-based therapies on renal function
- (2018) Vasilis Tsimihodimos et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes
- (2018) Sean L. Zheng et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The optimal blood pressure target in diabetes mellitus: a quest coming to an end?
- (2018) Eirini Papadopoulou et al. JOURNAL OF HUMAN HYPERTENSION
- Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
- (2018) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
- (2018) Katherine R Tuttle et al. Lancet Diabetes & Endocrinology
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
- (2018) Vlado Perkovic et al. Lancet Diabetes & Endocrinology
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
- (2018) M Angelyn Bethel et al. Lancet Diabetes & Endocrinology
- The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes
- (2018) Kelly R. McHugh et al. CLINICAL CARDIOLOGY
- SGLT1 inhibition: Pros and cons
- (2018) Vasilis Tsimihodimos et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Renoprotective effects of dulaglutide in patients with T2DM and CKD
- (2018) Charlotte M. Sorensen et al. Nature Reviews Nephrology
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
- (2018) Stephen C. Bain et al. DIABETES OBESITY & METABOLISM
- 2018 ESC/ESH Guidelines for the management of arterial hypertension
- (2018) Bryan Williams et al. JOURNAL OF HYPERTENSION
- The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction
- (2018) Jonathan D. Newman et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?
- (2018) Marion Mafham et al. LANCET
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial
- (2017) David Fitchett et al. EUROPEAN HEART JOURNAL
- A review of chemical therapies for treating diabetic hypertension
- (2017) Pantelis A. Sarafidis et al. EXPERT OPINION ON PHARMACOTHERAPY
- The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus
- (2017) Jens Jordan et al. Journal of the American Society of Hypertension
- Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME
- (2017) Pantelis A. Sarafidis et al. Nature Reviews Endocrinology
- GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
- (2017) Marcel H. A. Muskiet et al. Nature Reviews Nephrology
- Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor
- (2017) Michael Fralick et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
- (2017) Satish K. Garg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gastrointestinal–Renal Axis: Role in the Regulation of Blood Pressure
- (2017) Jian Yang et al. Journal of the American Heart Association
- Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
- (2017) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events
- (2017) Kenneth W. Mahaffey et al. CIRCULATION
- Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
- (2017) Christoph Wanner et al. CIRCULATION
- Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes
- (2016) Rajaa El Bekay et al. BRITISH JOURNAL OF PHARMACOLOGY
- The Cardiovascular Biology of Glucagon-like Peptide-1
- (2016) Daniel J. Drucker Cell Metabolism
- Empagliflozin’s Fuel Hypothesis: Not so Soon
- (2016) Gary D. Lopaschuk et al. Cell Metabolism
- EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus
- (2016) Guntram Schernthaner et al. CLINICAL THERAPEUTICS
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- The effect of liraglutide on renal function: A randomized clinical trial
- (2016) Bernt J. von Scholten et al. DIABETES OBESITY & METABOLISM
- Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
- (2016) Lennart Tonneijck et al. DIABETOLOGIA
- Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
- (2016) Antonius Baartscheer et al. DIABETOLOGIA
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction
- (2016) Kenneth B. Margulies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
- (2016) Hiddo J. L. Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
- (2016) Abd A. Tahrani et al. Nature Reviews Endocrinology
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals
- (2016) Tsutomu Hirano et al. Journal of Diabetes Investigation
- Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus
- (2016) Jean-Luc Faillie et al. JAMA Internal Medicine
- GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats
- (2015) Tomoaki Inoue et al. ATHEROSCLEROSIS
- Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
- (2015) Feng Sun et al. CLINICAL THERAPEUTICS
- Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis
- (2015) Tracey Gaspari et al. Diabetes & Vascular Disease Research
- Update of mortality attributable to diabetes for the IDF Diabetes Atlas: Estimates for the year 2013
- (2015) IDF Diabetes Atlas Group DIABETES RESEARCH AND CLINICAL PRACTICE
- Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
- (2015) Feng Sun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2015) Silvio E. Inzucchi et al. DIABETOLOGIA
- Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis
- (2015) A. Ojima et al. HORMONE AND METABOLIC RESEARCH
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes
- (2015) Bernt Johan von Scholten et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Sodium–glucose cotransporter-2 inhibitors and blood pressure decrease
- (2015) Konstantinos P. Imprialos et al. JOURNAL OF HYPERTENSION
- Incretin-based drugs and renoprotection—is hyperfiltration key?
- (2015) Lennart Tonneijck et al. KIDNEY INTERNATIONAL
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
- (2015) Caroline Bonner et al. NATURE MEDICINE
- Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR
- (2015) Guideline development group et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pleiotropic effects of type 2 diabetes management strategies on renal risk factors
- (2015) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?
- (2015) Jose Górriz et al. Journal of Clinical Medicine
- Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus
- (2014) Andrew Aylsworth et al. ANNALS OF PHARMACOTHERAPY
- Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment
- (2014) B. J. von Scholten et al. DIABETIC MEDICINE
- Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
- (2014) Marko Škrtić et al. DIABETOLOGIA
- GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
- (2014) Charles Pyke et al. ENDOCRINOLOGY
- Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis
- (2014) H. J. Lambers Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- The potential for renoprotection with incretin-based drugs
- (2014) Tetsuhiro Tanaka et al. KIDNEY INTERNATIONAL
- Sodium-glucose cotransport inhibitors: mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease: FIGURE 1:
- (2014) George Vlotides et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis
- (2014) Yuko Tashiro et al. PEPTIDES
- Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
- (2014) Naoto Terami et al. PLoS One
- Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism
- (2014) Nadia M. Krasner et al. PLoS One
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Do GLP-1-Based Therapies Increase Cancer Risk?
- (2013) M. A. Nauck et al. DIABETES CARE
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- Euglycemic progression: Worsening of diabetic retinopathy in poorly controlled type 2 diabetes in minorities
- (2013) A. Shurter et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
- (2013) J van Can et al. INTERNATIONAL JOURNAL OF OBESITY
- Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men
- (2013) Jeppe Skov et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Sodium–glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
- (2013) Richard E. Gilbert KIDNEY INTERNATIONAL
- Aggressive blood pressure reduction and renin–angiotensin system blockade in chronic kidney disease: time for re-evaluation?
- (2013) Pantelis A. Sarafidis et al. KIDNEY INTERNATIONAL
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
- (2013) Donald E. Kohan et al. KIDNEY INTERNATIONAL
- The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?
- (2013) Marcel H. A. Muskiet et al. Nature Reviews Nephrology
- Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
- (2013) Linda F. Fried et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?
- (2013) Usha Panchapakesan et al. PLoS One
- Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus
- (2013) Sonal Singh et al. JAMA Internal Medicine
- Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans
- (2012) Changting Xiao et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis
- (2012) S.-C. Liu et al. DIABETES OBESITY & METABOLISM
- Cardiorenal disease development under chronic renin–angiotensin–aldosterone system suppression
- (2012) Pantelis A Sarafidis et al. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
- Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
- (2012) Hans-Henrik Parving et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
- (2011) R. A. DeFronzo et al. DIABETES OBESITY & METABOLISM
- Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes
- (2011) R. Kodera et al. DIABETOLOGIA
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
- (2011) Michael Elashoff et al. GASTROENTEROLOGY
- Exenatide Exerts a Potent Antiinflammatory Effect
- (2011) Ajay Chaudhuri et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women
- (2010) Marie Therese Cooney et al. AMERICAN HEART JOURNAL
- How can we achieve global equity in provision of renal replacement therapy?
- (2010) Sarah White BULLETIN OF THE WORLD HEALTH ORGANIZATION
- Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition
- (2010) M. C. Bunck et al. DIABETES CARE
- The clinical significance of hyperfiltration in diabetes
- (2010) G. Jerums et al. DIABETOLOGIA
- Diuretics in clinical practice. Part II: electrolyte and acid-base disorders complicating diuretic therapy
- (2010) Pantelis A Sarafidis et al. Expert Opinion On Drug Safety
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
- (2010) The Emerging Risk Factors Collaboration LANCET
- Effects of Thiazolidinediones Beyond Glycaemic Control
- (2009) Rigas Kalaitzidis et al. CURRENT PHARMACEUTICAL DESIGN
- Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue
- (2009) J. Jendle et al. DIABETES OBESITY & METABOLISM
- The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice
- (2009) J. Hsieh et al. DIABETOLOGIA
- Heart Rate as a Risk Factor for Cardiovascular Disease
- (2009) Christine Perret-Guillaume et al. PROGRESS IN CARDIOVASCULAR DISEASES
- Effects of Renin-Angiotensin System Blockers on Renal Outcomes and All-cause Mortality in Patients With Diabetic Nephropathy: An Updated Meta-analysis
- (2008) P. A. Sarafidis et al. AMERICAN JOURNAL OF HYPERTENSION
- Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes
- (2008) Peter Gæde et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now